JMP Securities lowered the firm’s price target on Altimmune to $24 from $25 and keeps an Outperform rating on the shares. Data from the Phase 2b IMPACT trial of pemvidutide in NASH remains on track for 1Q25, where JMP thinks success on both the NASH resolution and fibrosis improvement endpoints is likely, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
- Altimmune call volume above normal and directionally bullish
- Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP
- Altimmune to Participate at Two Upcoming Investor Conferences
- Is ALT a Buy, Before Earnings?